OPTImal Treatment of Sinus VENOSUS Defect

Recruiting N/A Interventional Study
Sinus Venosus Defect Congenital Heart Disease Sinus Venosus Atrial Septum Defect
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
12 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
60 (estimated)
Sponsor
Centre Chirurgical Marie Lannelongue · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Sinus venosus defect (SVD) accounts for 10% of atrial septal defects and is characterized by an anomalous pulmonary venous return in the superior vena cava associated with a high situated atrial septal defect. Since 2013, transcatheter correction of this congenital heart disease has emerged as a new treatment option. The procedure involves placement of a covered stent in the superior vena cava tha…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * from 12 years of age * SVD with right ventricular end-diastolic volume dilatation (RV EDV) on imaging (echocardiography and/or MRI), defined by the guidelines as RV EDV greater than 112mL/m2 for women and 121 mL/m2 for men. * With an indication for atrial septal defect correct…
Contacts

SEBASTIEN HASCOËT

+33140942429

s.hascoet@ghpsj.fr

CONTACT

FLORENCE LECERF

+33140942517

f.lecerf@ghpsj.fr

CONTACT